CO5170520A1 - Derivados de 4-(fenil sustituido)-2-piperazinil-pirimidin-(3,5-bistrifluoro-metil-bencil)- metil-amida - Google Patents

Derivados de 4-(fenil sustituido)-2-piperazinil-pirimidin-(3,5-bistrifluoro-metil-bencil)- metil-amida

Info

Publication number
CO5170520A1
CO5170520A1 CO00039590A CO00039590A CO5170520A1 CO 5170520 A1 CO5170520 A1 CO 5170520A1 CO 00039590 A CO00039590 A CO 00039590A CO 00039590 A CO00039590 A CO 00039590A CO 5170520 A1 CO5170520 A1 CO 5170520A1
Authority
CO
Colombia
Prior art keywords
alkyl
metil
hydrogen
alkoxy
halogen
Prior art date
Application number
CO00039590A
Other languages
English (en)
Inventor
Michael Bos
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5170520A1 publication Critical patent/CO5170520A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la fórmula general<EMI FILE="00039590_1" ID="1" IMF=JPEG >en dondeR1 es hidrógeno o halógeno;R2 es hidrógeno, halógeno, alquilo C1-C7 ó alcoxilo C1-C7;R1 y R2 pueden ser junto con los dos átomos de carbono del anillo -CH=CH-CH=CH-;R3 es halógeno, trifluorometilo, alquilo C1-C7 ó alcoxilo C1-C7;R4/R4´ son independientemente uno de otro hidrógeno ó alquilo C1-C7;R5 es alquilo C1-C7, alcoxilo C1-C7, amino, fenilo, hidroxi-alquilo C1-C7, ciano-alquilo C1-C7, carbamoílo-alquilo C1-C7, piridilo, pirimidilo, -(CH2)n-piperazinilo, el cual se encuentra substituido opcionalmente por uno o dos grupos alquilo C1-C7 ó por hidroxi-alquilo C1-C7, -(CH2)n-morfolinilo, -(CH2)n-piperidinilo, -(CH2)n+1-imidazolilo, alquilo C1-C7-sulfanilo, alquilo C1-C7-sulfonilo, bencilamino, -NH-(CH2)n+1N(R4")2, -(CH2)n+1N(R4")2, -O-(CH2)n+1-morfolinilo, -O-(CH2)n+1-piperidinilo ó -O-(CH2)n+1N(R4")2, en donde R4" es hidrógeno ó alquilo C1-C7; yn es O-2;X es -C(O)N(R4")- ó -N(R4")C(O)-;y sales derivadas de una adición ácida farmacéuticamente aceptables.
CO00039590A 1999-05-31 2000-05-29 Derivados de 4-(fenil sustituido)-2-piperazinil-pirimidin-(3,5-bistrifluoro-metil-bencil)- metil-amida CO5170520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99110483 1999-05-31

Publications (1)

Publication Number Publication Date
CO5170520A1 true CO5170520A1 (es) 2002-06-27

Family

ID=8238271

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00039590A CO5170520A1 (es) 1999-05-31 2000-05-29 Derivados de 4-(fenil sustituido)-2-piperazinil-pirimidin-(3,5-bistrifluoro-metil-bencil)- metil-amida

Country Status (36)

Country Link
US (1) US6274588B1 (es)
EP (1) EP1187815B1 (es)
JP (1) JP3590592B2 (es)
KR (1) KR100440106B1 (es)
CN (1) CN1166643C (es)
AR (1) AR024146A1 (es)
AT (1) ATE317389T1 (es)
AU (1) AU770786B2 (es)
BR (1) BR0011127A (es)
CA (1) CA2375671C (es)
CO (1) CO5170520A1 (es)
CZ (1) CZ20014271A3 (es)
DE (1) DE60025918T2 (es)
DK (1) DK1187815T3 (es)
ES (1) ES2257294T3 (es)
GC (1) GC0000191A (es)
HK (1) HK1046528B (es)
HR (1) HRP20010871A2 (es)
HU (1) HUP0201315A3 (es)
IL (2) IL146460A0 (es)
JO (1) JO2261B1 (es)
MA (1) MA26793A1 (es)
MX (1) MXPA01012089A (es)
MY (1) MY122731A (es)
NO (1) NO321354B1 (es)
NZ (1) NZ515407A (es)
PE (1) PE20010153A1 (es)
PL (1) PL353441A1 (es)
PT (1) PT1187815E (es)
RU (1) RU2243221C2 (es)
SI (1) SI1187815T1 (es)
TR (1) TR200103457T2 (es)
TW (1) TW550258B (es)
WO (1) WO2000073279A1 (es)
YU (1) YU84901A (es)
ZA (1) ZA200109163B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU2001284504A1 (en) * 2000-09-14 2002-03-26 Ajinomoto Co., Inc. Novel pyrimidine derivative and novel pyridine derivative
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
EP1679309A4 (en) * 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
HUP0400405A3 (en) * 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
WO2006050476A2 (en) * 2004-11-03 2006-05-11 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
CA2601935C (en) * 2005-02-22 2013-04-09 F. Hoffmann-La Roche Ag Nk1 antagonists
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
EP1890703B1 (en) * 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidine compounds as chemokine receptors inhibitors
US8372849B2 (en) 2008-04-21 2013-02-12 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
EP3250034B1 (en) * 2015-01-30 2020-03-11 Basf Se Herbicidal phenylpyrimidines
KR102335082B1 (ko) * 2017-01-10 2021-12-06 내셔날 헬스 리서치 인스티튜트 헤테로사이클릭 화합물 및 이의 용도
KR102006547B1 (ko) * 2017-11-16 2019-08-01 서울대학교산학협력단 벤즈아미드 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 염증질환의 치료 또는 예방용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
DE3614060A1 (de) * 1986-04-23 1987-10-29 Schering Ag Pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
BR9408442A (pt) 1993-12-29 1997-08-05 Merck Sharp & Dohme Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto
JPH11512399A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
US6274588B1 (en) 2001-08-14
JP2003500478A (ja) 2003-01-07
BR0011127A (pt) 2002-02-19
MA26793A1 (fr) 2004-12-20
HRP20010871A2 (en) 2003-04-30
EP1187815B1 (en) 2006-02-08
HUP0201315A3 (en) 2003-02-28
DE60025918T2 (de) 2006-09-28
PL353441A1 (en) 2003-11-17
TW550258B (en) 2003-09-01
CZ20014271A3 (cs) 2002-05-15
NZ515407A (en) 2004-03-26
JO2261B1 (en) 2004-10-07
CN1353697A (zh) 2002-06-12
CA2375671C (en) 2009-08-25
AR024146A1 (es) 2002-09-04
ATE317389T1 (de) 2006-02-15
IL146460A (en) 2006-10-31
KR20020000826A (ko) 2002-01-05
JP3590592B2 (ja) 2004-11-17
NO20015700D0 (no) 2001-11-22
YU84901A (sh) 2004-09-03
AU770786B2 (en) 2004-03-04
ZA200109163B (en) 2003-02-06
MXPA01012089A (es) 2002-06-04
HUP0201315A2 (hu) 2002-12-28
AU4567700A (en) 2000-12-18
DE60025918D1 (de) 2006-04-20
SI1187815T1 (sl) 2006-06-30
ES2257294T3 (es) 2006-08-01
NO321354B1 (no) 2006-05-02
IL146460A0 (en) 2002-07-25
MY122731A (en) 2006-04-29
GC0000191A (en) 2006-03-29
EP1187815A1 (en) 2002-03-20
WO2000073279A1 (en) 2000-12-07
TR200103457T2 (tr) 2002-04-22
NO20015700L (no) 2001-11-22
PE20010153A1 (es) 2001-02-08
CN1166643C (zh) 2004-09-15
KR100440106B1 (ko) 2004-07-14
PT1187815E (pt) 2006-06-30
CA2375671A1 (en) 2000-12-07
HK1046528A1 (en) 2003-01-17
RU2243221C2 (ru) 2004-12-27
HK1046528B (zh) 2005-02-25
DK1187815T3 (da) 2006-06-19

Similar Documents

Publication Publication Date Title
CO5170520A1 (es) Derivados de 4-(fenil sustituido)-2-piperazinil-pirimidin-(3,5-bistrifluoro-metil-bencil)- metil-amida
TW200738682A (en) Isoquinoline derivatives
CO5200785A1 (es) Uso terapeutico de quinazolina
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
HUP0002112A2 (hu) Helyettesített 3-ciano-kinolinok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
TW200716528A (en) Cyclopropanecarboxamide derivatives
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
CO5320599A1 (es) Inhibidores no peptidilicos de la union a las celulas depen dientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
AR024145A1 (es) Derivados de 5-fenil-pirimidina
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
CO5160261A1 (es) Derivados de bifenilo sustituidos que son antagonistas nk-1, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
MY131762A (en) Pharmaceutical compounds
EP0351255A3 (en) Derivatives of û2-(4-piperidinyl)methyl¨-1,2,3,4-tetrahydroisoquinoline, their preparation and their use in therapy
DE60009868D1 (en) Anti-tumor dihydrochinazolindervate
CO5180624A1 (es) Antagonistas muscarinicos
AU8519601A (en) 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents
ES2090238T3 (es) Derivados benzhidriloxietilpiperidilos de acidos alifaticos y su aplicacion en el tratamiento del asma y de sus alergias.
MXPA04002838A (es) Derivados de alquilaminopiridazinona sustituidos, procedimiento para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
AR046574A1 (es) Ligandos del receptor 5-ht2a
ATE238300T1 (de) (3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl)-3-(1 - indol-3-yl)-alkylamine
CO5140085A1 (es) Derivados terapeuticos de benzamida
MY118064A (en) Pharmaceutical composition and method for the control of hypertension

Legal Events

Date Code Title Description
FD Application lapsed